Navigation Links
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
Date:12/20/2007

MISSISSAUGA, ON, Dec. 20 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it has completed accrual in the first 50-patient cohort of its Phase II trial of nimotuzumab in combination with irinotecan for the treatment of colorectal cancer. The safety profile in the trial to date is consistent with data from previous trials of nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), in that there has been no evidence of the severe side effects frequently seen with currently approved EGFR-targeting antibodies and small molecules.

"We are pleased by the enthusiasm of the investigators that resulted in rapid enrollment of this patient cohort and look forward to results from this trial which could provide the evidence to advance nimotuzumab's further development in one of the largest cancer patient populations," said David Allan, Chairman and CEO of YM BioSciences. "Preliminary data on disease control rates should be available toward the end of the first calendar quarter of 2008. Since progression-free survival (PFS) in this patient population historically approximates four months initial observations of nimotuzumab's effect on PFS could be available shortly after the response data."

The single-arm trial in Canada is currently designed to enroll 100 patients in two 50-patient cohorts, consecutively, with the first cohort receiving irinotecan and weekly dosing of nimotuzumab and the second cohort receiving irinotecan with nimotuzumab every two weeks. The endpoints of the trial include the rate and duration of disease control (Stabl
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... Vernon Hills, IL (PRWEB) January 15, 2014 ... Cole-Parmer to find hard-working items for the lab, from ... designated as Guaranteed-in-Stock (GIS)—ready to ship when you order. ... Masterflex® Peristaltic Pumps , from the L/S® model ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... , June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris ... a late-stage drug development company specialized in oncology and ... announced registered direct offering of US$12.1 million ... purchase warrants to certain institutional investors. Net proceeds from ...
... June 21, 2010 The Pharmaceutical practice,at MarketsandMarkets is pleased to announce a new report ... , ... , , ... , , ...
... in power capacity as a result of a new finding ... for one of the battery,s electrodes produced a significant increase ... it could deliver from a given weight of material, compared ... in small portable devices, and with further research might also ...
Cached Biology Technology:Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 2Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 2Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 3Top 10 Drug Delivery Technologies (2010 - 2015): MarketsandMarkets 4Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 2Using carbon nanotubes in lithium batteries can dramatically improve energy capacity 3
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
(Date:7/9/2014)... southern Europe are less fit in terms of ... European peers. Moreover, southern adolescents are more obese ... fat than those from the centre-north of Europe. ... from an ambitious study conducted by scientists from ... in collaboration with 25 other European research groups. ...
(Date:7/9/2014)... yield big savings, if they are used in ... the Brigham and Women,s Hospital and coauthors analyzed ... savingshigh-cost patients; readmissions; triage; decompensation (when a patient,s ... a disease affects multiple organ systems. They suspect ... current costs associated with all six scenarios will ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... CITY, MO Cells trying to keep pace with constantly ... between maintaining their genomic integrity and allowing enough genetic ... study, researchers at the Stowers Institute for Medical Research ... genomes become unstable, readily acquiring or losing whole chromosomes ...
... the genetic variance of human metabolism, researchers have identified ... with levels of circulating metabolites, i.e., small molecules that ... Many of the studied metabolites are biomarkers for cardiovascular ... provide valuable insight into the biological processes leading to ...
... the researchers to see an aspect of light that humans ... sensitive to polarized light, many reef dwelling animals are but ... studies of reef communities. Thanks to generous support provided ... team of researchers from the Ecology of Vision Laboratory in ...
Cached Biology News:That which does not kill yeast makes it stronger 2That which does not kill yeast makes it stronger 3Genetic regulation of metabolomic biomarkers - paths to cardiovascular diseases and type 2 diabetes 2Capturing an octopus-eye view of the Great Barrier Reef 2
... The mycobacteria in Complete Freund's adjuvant attract ... site which enhances the immuneresponse. For this ... for the initial injections; Incomplete Freund's adjuvant ... (preferably in saline) are typically mixed with ...
The ELISA Kit for Hepatitis B Surface Antigen (HBsAg) is an in vitro enzyme immunoassay for the detection of HBsAg in human serum or plasma....
2,4-Dinitrophenyl hapten is conjugated to Keyhole Limpet (KLH) protein through lysine....
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
Biology Products: